nodes	percent_of_prediction	percent_of_DWPC	metapath
Azilsartan medoxomil—Losartan—UGT2B17—prostate cancer	0.02	0.651	CrCbGaD
Azilsartan medoxomil—Skin disorder—Flutamide—prostate cancer	0.00498	0.00679	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Conjugated Estrogens—prostate cancer	0.00488	0.00666	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Abiraterone—prostate cancer	0.00486	0.00664	CcSEcCtD
Azilsartan medoxomil—Fatigue—Abiraterone—prostate cancer	0.00486	0.00663	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Etoposide—prostate cancer	0.0048	0.00655	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Degarelix—prostate cancer	0.00476	0.0065	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Bicalutamide—prostate cancer	0.00474	0.00648	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Estradiol valerate/Dienogest—prostate cancer	0.00474	0.00647	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Etoposide—prostate cancer	0.00453	0.00619	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Degarelix—prostate cancer	0.00451	0.00616	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Cabazitaxel—prostate cancer	0.00449	0.00613	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Degarelix—prostate cancer	0.00447	0.0061	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Nilutamide—prostate cancer	0.00444	0.00607	CcSEcCtD
Azilsartan medoxomil—Fatigue—Flutamide—prostate cancer	0.00442	0.00603	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Bicalutamide—prostate cancer	0.00438	0.00598	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Ethinyl Estradiol—prostate cancer	0.00434	0.00593	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Cabazitaxel—prostate cancer	0.00425	0.0058	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Cabazitaxel—prostate cancer	0.00421	0.00574	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Estradiol valerate/Dienogest—prostate cancer	0.00418	0.0057	CcSEcCtD
Azilsartan medoxomil—Fatigue—Estradiol valerate/Dienogest—prostate cancer	0.00417	0.00569	CcSEcCtD
Azilsartan medoxomil—Angioedema—Bicalutamide—prostate cancer	0.00416	0.00568	CcSEcCtD
Azilsartan medoxomil—Pruritus—Estramustine—prostate cancer	0.0041	0.0056	CcSEcCtD
Azilsartan medoxomil—Asthenia—Abiraterone—prostate cancer	0.00404	0.00552	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Ethinyl Estradiol—prostate cancer	0.00401	0.00548	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Degarelix—prostate cancer	0.00397	0.00542	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Estramustine—prostate cancer	0.00397	0.00542	CcSEcCtD
Azilsartan medoxomil—Fatigue—Degarelix—prostate cancer	0.00396	0.00541	CcSEcCtD
Azilsartan medoxomil—Pruritus—Estrone—prostate cancer	0.00392	0.00535	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Abiraterone—prostate cancer	0.00385	0.00526	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Bicalutamide—prostate cancer	0.00385	0.00525	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Cabazitaxel—prostate cancer	0.00374	0.0051	CcSEcCtD
Azilsartan medoxomil—Fatigue—Cabazitaxel—prostate cancer	0.00373	0.0051	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Ethinyl Estradiol—prostate cancer	0.0037	0.00505	CcSEcCtD
Azilsartan medoxomil—Asthenia—Nilutamide—prostate cancer	0.00369	0.00504	CcSEcCtD
Azilsartan medoxomil—Asthenia—Flutamide—prostate cancer	0.00368	0.00502	CcSEcCtD
Azilsartan medoxomil—Dizziness—Estrone—prostate cancer	0.00366	0.005	CcSEcCtD
Azilsartan medoxomil—Rash—Estramustine—prostate cancer	0.00366	0.00499	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Estramustine—prostate cancer	0.00365	0.00499	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Bicalutamide—prostate cancer	0.00364	0.00497	CcSEcCtD
Azilsartan medoxomil—Pruritus—Nilutamide—prostate cancer	0.00364	0.00497	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Mitoxantrone—prostate cancer	0.00364	0.00497	CcSEcCtD
Azilsartan medoxomil—Pruritus—Flutamide—prostate cancer	0.00363	0.00495	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Bicalutamide—prostate cancer	0.00361	0.00493	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Goserelin—prostate cancer	0.00358	0.00489	CcSEcCtD
Azilsartan medoxomil—Rash—Abiraterone—prostate cancer	0.00355	0.00485	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Conjugated Estrogens—prostate cancer	0.00355	0.00485	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Abiraterone—prostate cancer	0.00355	0.00484	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Nilutamide—prostate cancer	0.00352	0.00481	CcSEcCtD
Azilsartan medoxomil—Angioedema—Ethinyl Estradiol—prostate cancer	0.00352	0.0048	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Flutamide—prostate cancer	0.00351	0.00479	CcSEcCtD
Azilsartan medoxomil—Rash—Estrone—prostate cancer	0.00349	0.00477	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Estrone—prostate cancer	0.00349	0.00477	CcSEcCtD
Azilsartan medoxomil—Asthenia—Estradiol valerate/Dienogest—prostate cancer	0.00347	0.00474	CcSEcCtD
Azilsartan medoxomil—Nausea—Estramustine—prostate cancer	0.00345	0.0047	CcSEcCtD
Azilsartan medoxomil—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.00342	0.00467	CcSEcCtD
Azilsartan medoxomil—Dizziness—Nilutamide—prostate cancer	0.0034	0.00465	CcSEcCtD
Azilsartan medoxomil—Dizziness—Flutamide—prostate cancer	0.00339	0.00463	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Goserelin—prostate cancer	0.0033	0.00451	CcSEcCtD
Azilsartan medoxomil—Asthenia—Degarelix—prostate cancer	0.0033	0.0045	CcSEcCtD
Azilsartan medoxomil—Nausea—Estrone—prostate cancer	0.00329	0.00449	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Conjugated Estrogens—prostate cancer	0.00327	0.00446	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—prostate cancer	0.00325	0.00444	CcSEcCtD
Azilsartan medoxomil—Pruritus—Degarelix—prostate cancer	0.00325	0.00444	CcSEcCtD
Azilsartan medoxomil—Rash—Nilutamide—prostate cancer	0.00325	0.00443	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Nilutamide—prostate cancer	0.00324	0.00443	CcSEcCtD
Azilsartan medoxomil—Rash—Flutamide—prostate cancer	0.00323	0.00441	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Flutamide—prostate cancer	0.00323	0.00441	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Bicalutamide—prostate cancer	0.00321	0.00438	CcSEcCtD
Azilsartan medoxomil—Fatigue—Bicalutamide—prostate cancer	0.0032	0.00437	CcSEcCtD
Azilsartan medoxomil—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.0032	0.00437	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Degarelix—prostate cancer	0.00315	0.00429	CcSEcCtD
Azilsartan medoxomil—Asthenia—Cabazitaxel—prostate cancer	0.00311	0.00424	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Ethinyl Estradiol—prostate cancer	0.00308	0.0042	CcSEcCtD
Azilsartan medoxomil—Nausea—Nilutamide—prostate cancer	0.00306	0.00417	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Ethinyl Estradiol—prostate cancer	0.00305	0.00416	CcSEcCtD
Azilsartan medoxomil—Rash—Estradiol valerate/Dienogest—prostate cancer	0.00305	0.00416	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.00305	0.00416	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Goserelin—prostate cancer	0.00304	0.00416	CcSEcCtD
Azilsartan medoxomil—Nausea—Flutamide—prostate cancer	0.00304	0.00415	CcSEcCtD
Azilsartan medoxomil—Dizziness—Degarelix—prostate cancer	0.00304	0.00415	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Conjugated Estrogens—prostate cancer	0.00302	0.00412	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Cabazitaxel—prostate cancer	0.00296	0.00405	CcSEcCtD
Azilsartan medoxomil—Rash—Degarelix—prostate cancer	0.0029	0.00396	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Degarelix—prostate cancer	0.0029	0.00395	CcSEcCtD
Azilsartan medoxomil—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.00287	0.00392	CcSEcCtD
Azilsartan medoxomil—Angioedema—Conjugated Estrogens—prostate cancer	0.00287	0.00391	CcSEcCtD
Azilsartan medoxomil—Dizziness—Cabazitaxel—prostate cancer	0.00286	0.00391	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Estradiol—prostate cancer	0.00284	0.00388	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Estradiol—prostate cancer	0.00283	0.00387	CcSEcCtD
Azilsartan medoxomil—Nausea—Degarelix—prostate cancer	0.00273	0.00373	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.00271	0.0037	CcSEcCtD
Azilsartan medoxomil—Fatigue—Ethinyl Estradiol—prostate cancer	0.00271	0.0037	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Epirubicin—prostate cancer	0.00269	0.00367	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Goserelin—prostate cancer	0.00268	0.00366	CcSEcCtD
Azilsartan medoxomil—Asthenia—Bicalutamide—prostate cancer	0.00267	0.00364	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—prostate cancer	0.00265	0.00362	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—MC2R—prostate cancer	0.00264	0.0112	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CXCL12—prostate cancer	0.00263	0.0111	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Bicalutamide—prostate cancer	0.00263	0.00359	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Estradiol—prostate cancer	0.00262	0.00357	CcSEcCtD
Azilsartan medoxomil—Telmisartan—CYP2C19—prostate cancer	0.00261	0.0851	CrCbGaD
Azilsartan medoxomil—Nausea—Cabazitaxel—prostate cancer	0.00257	0.00351	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Bicalutamide—prostate cancer	0.00254	0.00347	CcSEcCtD
Azilsartan medoxomil—Blood uric acid increased—Epirubicin—prostate cancer	0.00254	0.00347	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Goserelin—prostate cancer	0.00253	0.00346	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—GRPR—prostate cancer	0.00252	0.0106	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.00251	0.00343	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Goserelin—prostate cancer	0.00251	0.00343	CcSEcCtD
Azilsartan medoxomil—Hyperuricaemia—Doxorubicin—prostate cancer	0.00249	0.0034	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Conjugated Estrogens—prostate cancer	0.00249	0.00339	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CASP9—prostate cancer	0.00248	0.0105	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Bicalutamide—prostate cancer	0.00246	0.00335	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—RLN2—prostate cancer	0.00245	0.0104	CbGpPWpGaD
Azilsartan medoxomil—Blood creatinine increased—Capecitabine—prostate cancer	0.00244	0.00332	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Estradiol—prostate cancer	0.00241	0.0033	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—PENK—prostate cancer	0.00236	0.00995	CbGpPWpGaD
Azilsartan medoxomil—Blood uric acid increased—Doxorubicin—prostate cancer	0.00235	0.00321	CcSEcCtD
Azilsartan medoxomil—Rash—Bicalutamide—prostate cancer	0.00234	0.0032	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Bicalutamide—prostate cancer	0.00234	0.0032	CcSEcCtD
Azilsartan medoxomil—Angioedema—Estradiol—prostate cancer	0.00229	0.00313	CcSEcCtD
Azilsartan medoxomil—Asthenia—Ethinyl Estradiol—prostate cancer	0.00225	0.00308	CcSEcCtD
Azilsartan medoxomil—Fatigue—Goserelin—prostate cancer	0.00223	0.00304	CcSEcCtD
Azilsartan medoxomil—Pruritus—Ethinyl Estradiol—prostate cancer	0.00222	0.00303	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.00221	0.00302	CcSEcCtD
Azilsartan medoxomil—Fatigue—Conjugated Estrogens—prostate cancer	0.00221	0.00301	CcSEcCtD
Azilsartan medoxomil—Nausea—Bicalutamide—prostate cancer	0.00221	0.00301	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—GRPR—prostate cancer	0.00216	0.00912	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.00215	0.00293	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—INS—prostate cancer	0.00213	0.00898	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.00212	0.0029	CcSEcCtD
Azilsartan medoxomil—Dizziness—Ethinyl Estradiol—prostate cancer	0.00208	0.00284	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—MC2R—prostate cancer	0.00207	0.00874	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—CDH1—prostate cancer	0.00207	0.00873	CbGpPWpGaD
Azilsartan medoxomil—Tasosartan—CYP3A4—prostate cancer	0.00204	0.0664	CrCbGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GNRH1—prostate cancer	0.00203	0.00857	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Etoposide—prostate cancer	0.00203	0.00277	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Estradiol—prostate cancer	0.00201	0.00274	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL10—prostate cancer	0.002	0.00843	CbGpPWpGaD
Azilsartan medoxomil—Losartan—CYP3A5—prostate cancer	0.00199	0.065	CrCbGaD
Azilsartan medoxomil—Skin disorder—Estradiol—prostate cancer	0.00199	0.00272	CcSEcCtD
Azilsartan medoxomil—Rash—Ethinyl Estradiol—prostate cancer	0.00198	0.0027	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00198	0.0027	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GRP—prostate cancer	0.00196	0.0083	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—LPAR1—prostate cancer	0.00196	0.0083	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—PLCB2—prostate cancer	0.00194	0.00821	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—GRP—prostate cancer	0.00194	0.00819	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—prostate cancer	0.00189	0.008	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CX3CL1—prostate cancer	0.00188	0.00795	CbGpPWpGaD
Azilsartan medoxomil—Muscle spasms—Etoposide—prostate cancer	0.00187	0.00255	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—RLN2—prostate cancer	0.00187	0.00789	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Ethinyl Estradiol—prostate cancer	0.00187	0.00255	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—FASLG—prostate cancer	0.00186	0.00784	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Goserelin—prostate cancer	0.00185	0.00253	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Mitoxantrone—prostate cancer	0.00185	0.00253	CcSEcCtD
Azilsartan medoxomil—Losartan—ACE—prostate cancer	0.00184	0.0599	CrCbGaD
Azilsartan medoxomil—Asthenia—Conjugated Estrogens—prostate cancer	0.00184	0.00251	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Docetaxel—prostate cancer	0.00183	0.0025	CcSEcCtD
Azilsartan medoxomil—Pruritus—Goserelin—prostate cancer	0.00183	0.0025	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Docetaxel—prostate cancer	0.00183	0.00249	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—prostate cancer	0.00181	0.00766	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Conjugated Estrogens—prostate cancer	0.00181	0.00247	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—FGF2—prostate cancer	0.0018	0.0076	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—prostate cancer	0.00177	0.00749	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—MC2R—prostate cancer	0.00177	0.00749	CbGpPWpGaD
Azilsartan medoxomil—Oedema peripheral—Capecitabine—prostate cancer	0.00177	0.00242	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Estradiol—prostate cancer	0.00177	0.00241	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Goserelin—prostate cancer	0.00177	0.00241	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Capecitabine—prostate cancer	0.00177	0.00241	CcSEcCtD
Azilsartan medoxomil—Fatigue—Estradiol—prostate cancer	0.00177	0.00241	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—GNG5—prostate cancer	0.00176	0.00745	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—prostate cancer	0.00176	0.00742	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—LPAR1—prostate cancer	0.00176	0.00742	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Conjugated Estrogens—prostate cancer	0.00175	0.00239	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—SRC—prostate cancer	0.00175	0.00737	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PLCB2—prostate cancer	0.00174	0.00735	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Goserelin—prostate cancer	0.00171	0.00233	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Epirubicin—prostate cancer	0.0017	0.00232	CcSEcCtD
Azilsartan medoxomil—Dizziness—Conjugated Estrogens—prostate cancer	0.00169	0.00231	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Docetaxel—prostate cancer	0.00169	0.0023	CcSEcCtD
Azilsartan medoxomil—Fatigue—Mitoxantrone—prostate cancer	0.00165	0.00225	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.00165	0.00225	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GRPR—prostate cancer	0.00164	0.00694	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Capecitabine—prostate cancer	0.00163	0.00223	CcSEcCtD
Azilsartan medoxomil—Rash—Goserelin—prostate cancer	0.00163	0.00222	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Goserelin—prostate cancer	0.00163	0.00222	CcSEcCtD
Azilsartan medoxomil—Rash—Conjugated Estrogens—prostate cancer	0.00161	0.0022	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Conjugated Estrogens—prostate cancer	0.00161	0.0022	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—PENK—prostate cancer	0.00158	0.00667	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNG5—prostate cancer	0.00158	0.00667	CbGpPWpGaD
Azilsartan medoxomil—Connective tissue disorder—Prednisone—prostate cancer	0.00157	0.00215	CcSEcCtD
Azilsartan medoxomil—Blood creatinine increased—Doxorubicin—prostate cancer	0.00157	0.00214	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Docetaxel—prostate cancer	0.00155	0.00212	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Etoposide—prostate cancer	0.00154	0.00211	CcSEcCtD
Azilsartan medoxomil—Nausea—Goserelin—prostate cancer	0.00154	0.0021	CcSEcCtD
Azilsartan medoxomil—AGTR1—Arf6 signaling events—EGFR—prostate cancer	0.00153	0.00646	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Arf6 trafficking events—CTNNB1—prostate cancer	0.00153	0.00644	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Conjugated Estrogens—prostate cancer	0.00152	0.00208	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Capecitabine—prostate cancer	0.00151	0.00205	CcSEcCtD
Azilsartan medoxomil—Asthenia—Estradiol—prostate cancer	0.00147	0.00201	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Prednisone—prostate cancer	0.00145	0.00198	CcSEcCtD
Azilsartan medoxomil—Pruritus—Estradiol—prostate cancer	0.00145	0.00198	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—ANXA1—prostate cancer	0.00145	0.0061	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—ANXA1—prostate cancer	0.00143	0.00603	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—prostate cancer	0.00142	0.00599	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—WNT4—prostate cancer	0.00142	0.00598	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Estradiol—prostate cancer	0.0014	0.00191	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—OR51E2—prostate cancer	0.00139	0.00588	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Etoposide—prostate cancer	0.00137	0.00187	CcSEcCtD
Azilsartan medoxomil—Asthenia—Mitoxantrone—prostate cancer	0.00137	0.00187	CcSEcCtD
Azilsartan medoxomil—Fatigue—Etoposide—prostate cancer	0.00137	0.00187	CcSEcCtD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.00137	0.00187	CcSEcCtD
Azilsartan medoxomil—Losartan—CYP2C19—prostate cancer	0.00136	0.0442	CrCbGaD
Azilsartan medoxomil—Dizziness—Estradiol—prostate cancer	0.00135	0.00185	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—MC2R—prostate cancer	0.00135	0.0057	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—GNRH1—prostate cancer	0.00134	0.00567	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.00132	0.00181	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Mitoxantrone—prostate cancer	0.00131	0.00178	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL12—prostate cancer	0.00131	0.00551	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—GRP—prostate cancer	0.0013	0.00549	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—LPAR1—prostate cancer	0.0013	0.00549	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Docetaxel—prostate cancer	0.00129	0.00177	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—prostate cancer	0.00129	0.00546	CbGpPWpGaD
Azilsartan medoxomil—Rash—Estradiol—prostate cancer	0.00129	0.00176	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Estradiol—prostate cancer	0.00129	0.00176	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Docetaxel—prostate cancer	0.00128	0.00175	CcSEcCtD
Azilsartan medoxomil—Angioedema—Prednisone—prostate cancer	0.00127	0.00174	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—OR51E2—prostate cancer	0.00126	0.00534	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CX3CL1—prostate cancer	0.00126	0.00533	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Capecitabine—prostate cancer	0.00125	0.00171	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Capecitabine—prostate cancer	0.00124	0.00169	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Epirubicin—prostate cancer	0.00123	0.00169	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Epirubicin—prostate cancer	0.00123	0.00168	CcSEcCtD
Azilsartan medoxomil—Nausea—Estradiol—prostate cancer	0.00122	0.00166	CcSEcCtD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—PRKCQ—prostate cancer	0.00121	0.00509	CbGpPWpGaD
Azilsartan medoxomil—Rash—Mitoxantrone—prostate cancer	0.0012	0.00164	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PENK—prostate cancer	0.0012	0.00508	CbGpPWpGaD
Azilsartan medoxomil—Dermatitis—Mitoxantrone—prostate cancer	0.0012	0.00164	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RGS17—prostate cancer	0.00118	0.005	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.00118	0.00161	CcSEcCtD
Azilsartan medoxomil—Oedema peripheral—Doxorubicin—prostate cancer	0.00114	0.00156	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Docetaxel—prostate cancer	0.00114	0.00156	CcSEcCtD
Azilsartan medoxomil—Asthenia—Etoposide—prostate cancer	0.00114	0.00156	CcSEcCtD
Azilsartan medoxomil—Connective tissue disorder—Doxorubicin—prostate cancer	0.00114	0.00156	CcSEcCtD
Azilsartan medoxomil—Fatigue—Docetaxel—prostate cancer	0.00114	0.00155	CcSEcCtD
Azilsartan medoxomil—Angiopathy—Epirubicin—prostate cancer	0.00114	0.00155	CcSEcCtD
Azilsartan medoxomil—Nausea—Mitoxantrone—prostate cancer	0.00113	0.00155	CcSEcCtD
Azilsartan medoxomil—Pruritus—Etoposide—prostate cancer	0.00112	0.00153	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Prednisone—prostate cancer	0.00112	0.00152	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Prednisone—prostate cancer	0.00111	0.00151	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Capecitabine—prostate cancer	0.0011	0.00151	CcSEcCtD
Azilsartan medoxomil—Fatigue—Capecitabine—prostate cancer	0.0011	0.0015	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CXCL8—prostate cancer	0.00109	0.00461	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Etoposide—prostate cancer	0.00109	0.00148	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCQ—prostate cancer	0.00108	0.00456	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RGS17—prostate cancer	0.00108	0.00454	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—ITPR1—prostate cancer	0.00107	0.00453	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—RLN2—prostate cancer	0.00106	0.00446	CbGpPWpGaD
Azilsartan medoxomil—Angiopathy—Doxorubicin—prostate cancer	0.00105	0.00144	CcSEcCtD
Azilsartan medoxomil—Dizziness—Etoposide—prostate cancer	0.00105	0.00143	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Epirubicin—prostate cancer	0.00105	0.00143	CcSEcCtD
Azilsartan medoxomil—AGTR1—Allograft Rejection—CASP3—prostate cancer	0.00104	0.00441	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—IL2—prostate cancer	0.00104	0.0044	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GNRH1—prostate cancer	0.00102	0.00432	CbGpPWpGaD
Azilsartan medoxomil—Rash—Etoposide—prostate cancer	0.001	0.00137	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Etoposide—prostate cancer	0.001	0.00137	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—prostate cancer	0.000998	0.00422	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—LPAR1—prostate cancer	0.000991	0.00418	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GRP—prostate cancer	0.000991	0.00418	CbGpPWpGaD
Azilsartan medoxomil—Fatigue—Prednisone—prostate cancer	0.000981	0.00134	CcSEcCtD
Azilsartan medoxomil—Muscle spasms—Doxorubicin—prostate cancer	0.00097	0.00132	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PLXNB1—prostate cancer	0.000965	0.00408	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CX3CL1—prostate cancer	0.000962	0.00406	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—prostate cancer	0.000959	0.00405	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—RLN2—prostate cancer	0.000958	0.00405	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—ANXA1—prostate cancer	0.000957	0.00404	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Docetaxel—prostate cancer	0.000947	0.00129	CcSEcCtD
Azilsartan medoxomil—Nausea—Etoposide—prostate cancer	0.000943	0.00129	CcSEcCtD
Azilsartan medoxomil—Pruritus—Docetaxel—prostate cancer	0.000934	0.00127	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GRPR—prostate cancer	0.000929	0.00392	CbGpPWpGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000922	0.00126	CcSEcCtD
Azilsartan medoxomil—Asthenia—Capecitabine—prostate cancer	0.000917	0.00125	CcSEcCtD
Azilsartan medoxomil—Pruritus—Capecitabine—prostate cancer	0.000904	0.00123	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Docetaxel—prostate cancer	0.000903	0.00123	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—GNG5—prostate cancer	0.00089	0.00376	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—VEGFA—prostate cancer	0.000886	0.00374	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB2—prostate cancer	0.000877	0.0037	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PLXNB1—prostate cancer	0.000876	0.0037	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL12—prostate cancer	0.000876	0.0037	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Capecitabine—prostate cancer	0.000874	0.00119	CcSEcCtD
Azilsartan medoxomil—Nervous system disorder—Epirubicin—prostate cancer	0.000873	0.00119	CcSEcCtD
Azilsartan medoxomil—Dizziness—Docetaxel—prostate cancer	0.000873	0.00119	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Epirubicin—prostate cancer	0.000865	0.00118	CcSEcCtD
Azilsartan medoxomil—Losartan—CYP3A4—prostate cancer	0.000863	0.0281	CrCbGaD
Azilsartan medoxomil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000853	0.00116	CcSEcCtD
Azilsartan medoxomil—Dizziness—Capecitabine—prostate cancer	0.000845	0.00115	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GRPR—prostate cancer	0.000844	0.00356	CbGpPWpGaD
Azilsartan medoxomil—Rash—Docetaxel—prostate cancer	0.000832	0.00114	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Docetaxel—prostate cancer	0.000831	0.00113	CcSEcCtD
Azilsartan medoxomil—Asthenia—Prednisone—prostate cancer	0.000817	0.00111	CcSEcCtD
Azilsartan medoxomil—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—prostate cancer	0.000816	0.00344	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Allograft Rejection—TGFB1—prostate cancer	0.000814	0.00344	CbGpPWpGaD
Azilsartan medoxomil—Nervous system disorder—Doxorubicin—prostate cancer	0.000808	0.0011	CcSEcCtD
Azilsartan medoxomil—Rash—Capecitabine—prostate cancer	0.000806	0.0011	CcSEcCtD
Azilsartan medoxomil—Pruritus—Prednisone—prostate cancer	0.000805	0.0011	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Capecitabine—prostate cancer	0.000805	0.0011	CcSEcCtD
Azilsartan medoxomil—Skin disorder—Doxorubicin—prostate cancer	0.0008	0.00109	CcSEcCtD
Azilsartan medoxomil—Nausea—Docetaxel—prostate cancer	0.000784	0.00107	CcSEcCtD
Azilsartan medoxomil—Diarrhoea—Prednisone—prostate cancer	0.000779	0.00106	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—PTHLH—prostate cancer	0.000775	0.00327	CbGpPWpGaD
Azilsartan medoxomil—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000769	0.00105	CcSEcCtD
Azilsartan medoxomil—Fatigue—Epirubicin—prostate cancer	0.000767	0.00105	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—MC2R—prostate cancer	0.000763	0.00322	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Capecitabine—prostate cancer	0.000759	0.00104	CcSEcCtD
Azilsartan medoxomil—Dizziness—Prednisone—prostate cancer	0.000753	0.00103	CcSEcCtD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—prostate cancer	0.000751	0.00317	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—OR51E2—prostate cancer	0.000747	0.00315	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—ANXA1—prostate cancer	0.000729	0.00308	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—WNT4—prostate cancer	0.000726	0.00307	CbGpPWpGaD
Azilsartan medoxomil—Rash—Prednisone—prostate cancer	0.000718	0.00098	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Prednisone—prostate cancer	0.000717	0.000979	CcSEcCtD
Azilsartan medoxomil—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000711	0.000971	CcSEcCtD
Azilsartan medoxomil—Fatigue—Doxorubicin—prostate cancer	0.00071	0.000969	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MC2R—prostate cancer	0.000693	0.00293	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BMPR1B—prostate cancer	0.000683	0.00288	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CALCA—prostate cancer	0.000683	0.00288	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PENK—prostate cancer	0.00068	0.00287	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Prednisone—prostate cancer	0.000676	0.000923	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL12—prostate cancer	0.000667	0.00282	CbGpPWpGaD
Azilsartan medoxomil—Asthenia—Epirubicin—prostate cancer	0.000639	0.000872	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RGS17—prostate cancer	0.000635	0.00268	CbGpPWpGaD
Azilsartan medoxomil—Pruritus—Epirubicin—prostate cancer	0.00063	0.00086	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PENK—prostate cancer	0.000617	0.00261	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Epirubicin—prostate cancer	0.000609	0.000831	CcSEcCtD
Azilsartan medoxomil—Asthenia—Doxorubicin—prostate cancer	0.000591	0.000807	CcSEcCtD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—prostate cancer	0.000589	0.00249	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Epirubicin—prostate cancer	0.000589	0.000804	CcSEcCtD
Azilsartan medoxomil—Pruritus—Doxorubicin—prostate cancer	0.000583	0.000796	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GNRH1—prostate cancer	0.000578	0.00244	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—VIP—prostate cancer	0.000578	0.00244	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—ADRB2—prostate cancer	0.000572	0.00242	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RLN2—prostate cancer	0.000566	0.00239	CbGpPWpGaD
Azilsartan medoxomil—Diarrhoea—Doxorubicin—prostate cancer	0.000564	0.000769	CcSEcCtD
Azilsartan medoxomil—Rash—Epirubicin—prostate cancer	0.000561	0.000766	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Epirubicin—prostate cancer	0.000561	0.000766	CcSEcCtD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—LPAR1—prostate cancer	0.00056	0.00236	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GRP—prostate cancer	0.00056	0.00236	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PLCB2—prostate cancer	0.000554	0.00234	CbGpPWpGaD
Azilsartan medoxomil—Dizziness—Doxorubicin—prostate cancer	0.000545	0.000744	CcSEcCtD
Azilsartan medoxomil—AGTR1—Peptide ligand-binding receptors—CXCL8—prostate cancer	0.000541	0.00228	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HSD17B1—prostate cancer	0.00054	0.00228	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CTBP2—prostate cancer	0.00054	0.00228	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—prostate cancer	0.000537	0.00227	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PDE4D—prostate cancer	0.000529	0.00223	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Epirubicin—prostate cancer	0.000529	0.000722	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GNRH1—prostate cancer	0.000525	0.00222	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—VIP—prostate cancer	0.000525	0.00222	CbGpPWpGaD
Azilsartan medoxomil—Rash—Doxorubicin—prostate cancer	0.000519	0.000709	CcSEcCtD
Azilsartan medoxomil—Dermatitis—Doxorubicin—prostate cancer	0.000519	0.000708	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PLXNB1—prostate cancer	0.000518	0.00219	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GRP—prostate cancer	0.000508	0.00215	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—LPAR1—prostate cancer	0.000508	0.00215	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PLCB2—prostate cancer	0.000503	0.00213	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—GNG5—prostate cancer	0.000503	0.00212	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GRPR—prostate cancer	0.000498	0.0021	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CX3CL1—prostate cancer	0.000494	0.00208	CbGpPWpGaD
Azilsartan medoxomil—Nausea—Doxorubicin—prostate cancer	0.000489	0.000668	CcSEcCtD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL17RD—prostate cancer	0.000481	0.00203	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PDE4D—prostate cancer	0.00048	0.00203	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—GNG5—prostate cancer	0.000457	0.00193	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PTHLH—prostate cancer	0.000438	0.00185	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—WNT4—prostate cancer	0.000429	0.00181	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JUP—prostate cancer	0.000429	0.00181	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ANXA1—prostate cancer	0.000412	0.00174	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—RALBP1—prostate cancer	0.000409	0.00173	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MC2R—prostate cancer	0.000409	0.00173	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PTHLH—prostate cancer	0.000398	0.00168	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PRKACB—prostate cancer	0.000389	0.00164	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CALCA—prostate cancer	0.000386	0.00163	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PPP3CA—prostate cancer	0.00038	0.0016	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL12—prostate cancer	0.000377	0.00159	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ANXA1—prostate cancer	0.000374	0.00158	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PENK—prostate cancer	0.000365	0.00154	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	0.000363	0.00153	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—prostate cancer	0.000358	0.00151	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CALCA—prostate cancer	0.00035	0.00148	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GHR—prostate cancer	0.000348	0.00147	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—G alpha (q) signalling events—PIK3CA—prostate cancer	0.000348	0.00147	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PRKCQ—prostate cancer	0.000344	0.00145	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL12—prostate cancer	0.000342	0.00144	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—prostate cancer	0.000338	0.00143	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NRP1—prostate cancer	0.000334	0.00141	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ADRB2—prostate cancer	0.000323	0.00137	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—VAV3—prostate cancer	0.000315	0.00133	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PRKCQ—prostate cancer	0.000312	0.00132	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—prostate cancer	0.000311	0.00131	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GNRH1—prostate cancer	0.00031	0.00131	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VIP—prostate cancer	0.00031	0.00131	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—ITPR1—prostate cancer	0.000306	0.00129	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GRP—prostate cancer	0.0003	0.00127	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LPAR1—prostate cancer	0.0003	0.00127	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LRP2—prostate cancer	0.000297	0.00126	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PLCB2—prostate cancer	0.000297	0.00126	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ADRB2—prostate cancer	0.000294	0.00124	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CX3CL1—prostate cancer	0.000292	0.00123	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—P4HB—prostate cancer	0.000292	0.00123	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—VAV3—prostate cancer	0.000286	0.00121	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HIST1H2BG—prostate cancer	0.000286	0.00121	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GRB7—prostate cancer	0.000284	0.0012	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDE4D—prostate cancer	0.000284	0.0012	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—ITPR1—prostate cancer	0.000278	0.00117	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HIST1H4H—prostate cancer	0.000276	0.00117	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR ligand binding—CXCL8—prostate cancer	0.000276	0.00117	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—prostate cancer	0.000275	0.00116	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GNG5—prostate cancer	0.00027	0.00114	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTHLH—prostate cancer	0.000235	0.000993	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFBR1—prostate cancer	0.000235	0.000993	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKR1C3—prostate cancer	0.000231	0.000977	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRKACB—prostate cancer	0.00023	0.000971	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PPP3CA—prostate cancer	0.000224	0.000947	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—THBS1—prostate cancer	0.000224	0.000947	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ANXA1—prostate cancer	0.000221	0.000933	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRKCZ—prostate cancer	0.000217	0.000916	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CG—prostate cancer	0.000212	0.000895	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGFR4—prostate cancer	0.000209	0.000885	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PARP1—prostate cancer	0.000209	0.000885	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CALCA—prostate cancer	0.000207	0.000874	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL12—prostate cancer	0.000202	0.000854	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CG—prostate cancer	0.000193	0.000813	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CASP9—prostate cancer	0.00019	0.000804	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CD—prostate cancer	0.000186	0.000787	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PRKCQ—prostate cancer	0.000184	0.000779	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NGFR—prostate cancer	0.000184	0.000779	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAP3K7—prostate cancer	0.000182	0.00077	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGF10—prostate cancer	0.000175	0.00074	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ADRB2—prostate cancer	0.000173	0.000732	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—JAK2—prostate cancer	0.000171	0.000722	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—MAP2K1—prostate cancer	0.00017	0.00072	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CD—prostate cancer	0.000169	0.000715	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VAV3—prostate cancer	0.000169	0.000714	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFBR2—prostate cancer	0.000167	0.000704	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ITPR1—prostate cancer	0.000164	0.000693	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CB—prostate cancer	0.000162	0.000686	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IGF1R—prostate cancer	0.000157	0.000662	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—CXCL8—prostate cancer	0.000156	0.000659	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—JAK2—prostate cancer	0.000155	0.000656	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LPL—prostate cancer	0.00015	0.000635	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—IL2—prostate cancer	0.000149	0.00063	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PDGFRB—prostate cancer	0.000149	0.000629	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CB—prostate cancer	0.000148	0.000623	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ITGB3—prostate cancer	0.000145	0.000613	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—CXCL8—prostate cancer	0.000142	0.000599	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ERBB3—prostate cancer	0.000141	0.000595	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGFR2—prostate cancer	0.000141	0.000594	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL2—prostate cancer	0.000135	0.000572	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TERT—prostate cancer	0.000135	0.00057	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—HIF1A—prostate cancer	0.000129	0.000545	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—LEP—prostate cancer	0.000126	0.000532	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CAV1—prostate cancer	0.000125	0.000527	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KDR—prostate cancer	0.000123	0.000521	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ESR1—prostate cancer	0.00012	0.000508	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—BAD—prostate cancer	0.000117	0.000496	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CG—prostate cancer	0.000114	0.00048	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—APC—prostate cancer	0.000114	0.00048	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGF—prostate cancer	0.000112	0.000475	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IRS1—prostate cancer	0.000112	0.000475	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—GSK3B—prostate cancer	0.000109	0.000461	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—INS—prostate cancer	0.000108	0.000455	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CREBBP—prostate cancer	0.000105	0.000445	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IGF1—prostate cancer	0.000104	0.00044	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—EGFR—prostate cancer	0.000104	0.000438	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MAP2K1—prostate cancer	0.000101	0.000425	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CD—prostate cancer	0.0001	0.000422	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—PIK3CA—prostate cancer	9.9e-05	0.000418	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SERPINE1—prostate cancer	9.89e-05	0.000418	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—KRAS—prostate cancer	9.79e-05	0.000413	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—FGF2—prostate cancer	9.57e-05	0.000404	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—NOS3—prostate cancer	9.44e-05	0.000399	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—JAK2—prostate cancer	9.18e-05	0.000388	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—PIK3CA—prostate cancer	8.99e-05	0.00038	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MDM2—prostate cancer	8.96e-05	0.000378	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—ERBB2—prostate cancer	8.83e-05	0.000373	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CB—prostate cancer	8.72e-05	0.000368	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CXCL8—prostate cancer	8.38e-05	0.000354	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN1B—prostate cancer	8.18e-05	0.000345	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—GPCR downstream signaling—AKT1—prostate cancer	8.09e-05	0.000342	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CASP3—prostate cancer	8.02e-05	0.000339	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL2—prostate cancer	8e-05	0.000338	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—IL6—prostate cancer	7.96e-05	0.000336	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CCND1—prostate cancer	7.8e-05	0.00033	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CTNNB1—prostate cancer	7.73e-05	0.000326	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MMP9—prostate cancer	7.58e-05	0.00032	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—CDKN1A—prostate cancer	7.55e-05	0.000319	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PTEN—prostate cancer	7.53e-05	0.000318	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling by GPCR—AKT1—prostate cancer	7.35e-05	0.00031	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EP300—prostate cancer	7.18e-05	0.000303	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—SRC—prostate cancer	6.98e-05	0.000295	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—VEGFA—prostate cancer	6.8e-05	0.000287	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—STAT3—prostate cancer	6.74e-05	0.000284	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—MYC—prostate cancer	6.26e-05	0.000264	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TGFB1—prostate cancer	6.24e-05	0.000264	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—EGFR—prostate cancer	6.12e-05	0.000259	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—KRAS—prostate cancer	5.78e-05	0.000244	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—PIK3CA—prostate cancer	5.31e-05	0.000224	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—TP53—prostate cancer	5.14e-05	0.000217	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—IL6—prostate cancer	4.7e-05	0.000199	CbGpPWpGaD
Azilsartan medoxomil—AGTR1—Signaling Pathways—AKT1—prostate cancer	4.34e-05	0.000183	CbGpPWpGaD
